TLSA

Tiziana Life Sciences is a clinical-stage biotechnology company developing immunotherapies for neurodegenerative and neuroinflammatory diseases, with its lead program Foralumab, a fully human anti-CD3 monoclonal antibody in development for Secondary Progressive Multiple Sclerosis, Alzheimer's disease, and ALS via intranasal administration. The company is also developing TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody for inflammatory and oncology indications, though this program has been temporarily deprioritized to focus resources on Foralumab.

Pipeline

Catalyst Calendar